Merz Therapeutics acquires INBRIJA® and (F)AMPYRA® products from Acorda Therapeutics in the therapy areas of Multiple Sclerosis and Parkinson's disease worth 185 million USD
Merz Therapeutics acquires INBRIJA® and (F)AMPYRA® products from Acorda Therapeutics in the therapy areas of Multiple Sclerosis and Parkinson's disease worth 185 million USD
07/10/24, 6:40 PM
Location
frankfurt
pearl riverIndustry
therapeutics
biotechnology
health care
therapeutics
biotechnology
health care
Merz Therapeutics has successfully acquired the products INBRIJA® and (F)AMPYRA® from Acorda Therapeutics, Inc. for 185 million USD. This strategic acquisition strengthens Merz Therapeutics' market position in the Parkinson and Multiple Sclerosis (MS) segments and aligns with the company's global growth strategy. The acquisition aims to expand the company's product portfolio and provide sustainable results for a broader group of people with neurological diseases.
Company Info
Location
Frankfurt, Hesse, Germany
Company info
Merz Therapeutics, a business of Frankfurt-based Merz Group, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.